Abstract Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of
transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in …

There is a need to improve personalized immunosuppression in organ transplantation to
reduce premature graft loss. Biomarkers are needed to better detect rejection, asymptomatic …

Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the
SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for …

Introduction Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus.
Standard-of-care immunosuppressive therapies achieve poor complete renal response …

The aim of this work is to estimate the area‐under the blood concentration curve of
tacrolimus (TAC) following bid or qd dosing in organ transplant patients, using Xgboost …

Background Immunosuppression after kidney transplantation is mainly guided via plasma
tacrolimus trough level, which cannot sufficiently predict allograft rejection and infection. The …

Tacrolimus (FK506) is widely used in the prevention of organ transplant rejection and the
treatment of autoimmune diseases, but it is difficult to detect within the low and narrow …

What is known and objective Meropenem, a carbapenem antibiotic, is widely prescribed for
the treatment of life‐threatening infections. The main parameter associated with its …

Background: COVID-19 is a novel infectious disease caused by the severe acute respiratory
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …

The influence of pharmacogenetics in tacrolimus pharmacokinetics and pharmacodynamics
needs further investigation, considering its potential in assisting clinicians to predict the …